The objective of the NeoPlaTT trial is to test whether, among extremely preterm infants born at 23 0/7 to 26 6/7 weeks' gestation, a lower platelet transfusion threshold, compared to a higher threshold, improves survival without major or severe bleeding up to 40 0/7 weeks' postmenstrual age (PMA).
Thrombocytopenia, Neonatal, Platelet Transfusion, Infant, Newborn, Diseases, Infant, Extremely Low Birth Weight, Infant, Small for Gestational Age, Thrombosis
The objective of the NeoPlaTT trial is to test whether, among extremely preterm infants born at 23 0/7 to 26 6/7 weeks' gestation, a lower platelet transfusion threshold, compared to a higher threshold, improves survival without major or severe bleeding up to 40 0/7 weeks' postmenstrual age (PMA).
Neonatal Platelet Transfusion Threshold Trial
-
University of Alabama at Birmingham, Birmingham, Alabama, United States, 35233
Stanford University, Palo Alto, California, United States, 94304
Sharp Mary Birch Hospital for Women & Newborns, San Diego, California, United States, 92123
University of Colorado, Aurora, Colorado, United States, 80045
Emory University, Atlanta, Georgia, United States, 30303
Northwestern Lurie Children's Hospital of Chicago, Chicago, Illinois, United States, 60611
University of Iowa, Iowa City, Iowa, United States, 52242
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States, 02215
University of New Mexico, Albuquerque, New Mexico, United States, 87131
University of Rochester, Rochester, New York, United States, 14642
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
1 Hour to 48 Hours
ALL
Yes
NICHD Neonatal Research Network,
Ravi M Patel, MD, PRINCIPAL_INVESTIGATOR, Emory University
2031-04-30